Medical Lifting Sling Market Growth Is Expected To Reach USD 1.1 Billion By 2024

Long term care is required in case of chronic disorders and surgical treatment. Medical lifting slings are essential elements in long term care and post operative recovery as they assist in patient transfer and other purposes. Increasing prevalence of chronic disorders and subsequent surgical interventions are boosting the usage of these products thus contributing toward substantial market growth.

Home healthcare has emerged as an important area where treatment cost is much lower compared to in traditional healthcare settings. In addition, long term care and post operative recovery can be efficiently achieved in these settings. Hence, in the developed as well as developing regions home healthcare services are growing swiftly resulting in the considerable growth of this vertical.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• Nylon-based medical lifting slings segment held a commanding share in 2015 and is anticipated to grow at a lucrative rate. This can be attributed to their durability and resistance to the infections.
• Patient transfer is the primary application of these products, which held a dominating share in 2015. Universal slings, which have multiple utility, are also expected to gain a substantial share over the forecast period.
• Reusable lifting slings were the most used products in 2015. However, with the rising incidence of infections and hygiene issues, disposable products are used to a greater extent and are expected to exhibit healthy growth over the forecast period.
• Hospitals use these products to a large extent, as they purchase in bulk and they have a greater patient pool. This makes hospitals the largest end-user of medical lifting slings.
• On the other hand, with the growing awareness and streamlined policies for home healthcare services, the usage of these services is surging. As a result, the growing home healthcare vertical is anticipated to increase the usage of medical lifting slings, thus affecting the market positively.
• Europe dominated the global medical lifting slings vertical in 2015. Larger pool of geriatric patients, rising research funding in medical devices, and steadily increasing awareness amongst patients are the key growth governing factors for this region.
• Asia Pacific is projected to witness remunerative growth in the coming eight years. Policy reforms, increasing disposable income, and economic developments are anticipated to foster the usage of advanced treatment options, and consequently engender a high demand for medical lifting slings.
• Some of the key players in this vertical are Getinge Group (ArjoHuntleigh), Invacare Corporation, Hill-Rom, Joerns Healthcare LLC, Argo Medical, Inc., Prism Medical, DJO Global, V.Guldmann A/S, Spectra Care Group, and Drive Medical. Strategic initiatives undertaken by these market players include new product development, distribution enhancement, collaborations, mergers, and acquisitions.

Click Here For Access Full Report : https://goo.gl/EamM99

Cervical Cancer Diagnostic Market Growth Is Expected To Reach A Value Of USD 12 Billion By 2024

The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is expected to reach a value of USD 12 billion by 2024, according to a new report by Grand View Research, Inc. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.

On account of increasing adoption of Pap test, the number of deaths due to cervical cancer has declined significantly in past few years. It helps detect precancerous lesions at an early state and, thus, reduces the number of cervical cancer cases. The American Cancer Society stated that the cervical cancer cases in last 40 years in the U.S. have declined by more than 50%. Initially, the Pap test screening was carried out every year which lead to further unnecessary procedures. However, the American Cancer Society now recommends that women in the age group of 21 to 29 should undergo Pap test every 3 years.

View summary of this report, Click Here 

Further Key Findings from the Study Suggest:

• In 2015, the Pap testing segment held majority of the market share of 49.6%. The segment’s large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.
• In 2015, North America was the leading regional market with a revenue share of 48.3%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country’s large market share.
• Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 9.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region’s high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth
• This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.

Reference Link: https://goo.gl/l9uA2B

Intravenous (IV) Solutions Market Solutions Market Is Expected To Rereach A Value Of USD 13.79 billion by 2024

The global IV solutions market was valued at USD 6.9 billion in 2015 and is expected to reach a value of USD 13.79 billion by 2024. Key factors driving market expansion include the rapidly increasing natality rate including a high percentage of premature births and malnutrition.

Growing incidence rate of chronic diseases, such as cancer, is also fueling the demand for Total Parenteral Nutrition (TPN), which forms a vital part of the treatment. Intravenous nutrition helps sustain strength, maintains hydration levels in patients, and facilitates faster recovery. Cancer prevalence is forecasted to grow by 70% over the next few decades. This poses a colossal growth prospect for the market.

The regulatory bodies are approving high-quality products complying with faster patient recovery. In May 2016, Amanta Healthcare received approval for NaCl injection BP and Sterile water injection BP products. These products obtained Therapeutic Goods Administration approval granted by the Australian government.

The reimbursement scenario for IV nutrition is promising. In the U.S., Medicare covers up to 80% of the expenses of parenteral and enteral nutrition including physician services, medical equipment, and other related medical services. In the developing countries, increasing purchasing power compensates for the absence of reimbursement coverage thus sustaining the growth of this vertical.

View summary of this report, Click Here  
Further Key Findings From the Study Suggest:

• TPN dominated the market in 2015. TPN is administered to patients who are ‘nil by mouth’ or are afflicted with dysfunctional digestive systems. Around 2000 elderly deaths occur per annum due to malnutrition. With rising geriatric population and chronic, but manageable diseases, the demand for TPN is projected to grow over the forecast period.
• In 2015, North America dominated the market with a revenue share of around 40%. The region has a large geriatric population base comprising 45% long-term care residents and 40% hospitalized, elderly patients suffering from malnutrition. Moreover, in 2014, the region experienced a sharp shortage of IV fluids due to increased hospitalization of influenza patients. In response to the deficit, FDA initiatives were directed toward expediting the application review process and identifying potential new manufacturers.
• Asia Pacific is expected to emerge as the fastest growing region. The rising geriatric population in Japan and China, increasing tendencies of unhealthy food consumption, and low level of awareness is expected to promote the emergence of IV solutions market in this region.
• Fresenius Kabi AG, Baxter, B. Braun Melsungen AG, and Hospira are few players operating in the market. Mergers and acquisitions are certain strategic initiatives undertaken by the companies. For instance, Claris-Otsuka is a joint venture between Claris Lifesciences Ltd., Otsuka Pharmaceutical Co., Ltd., and Mitsui & Co., Ltd., Japan established in 2012. This joint venture focused on the manufacturing and marketing activities for IV nutrition products and offers products in various IV delivery systems.

Click Here For Access Full Report : https://goo.gl/Pe0Tss

Trauma and extremities market worth is expected to reach a value of USD 15.9 billion by 2024

The expansion is attributed to the increasing geriatric population base along with the growing incidence rate of target diseases such as osteoporosis.

Introduction of new technologies in terms of material, technique, and the non-invasive nature of the employed material are augmenting the market growth. In July 2016, DePuy Synthes launched a new hand locking system used for deformities and fracture fixation. This device is designed to reduce soft tissue irritation and facilitate healing.

Moreover, companies are investing in new product development, which is anticipated to aid the future growth of the market. In 2015, Smith & Nephew invested USD 222 million on research and development, yielding a promising product pipeline for 2016. It has already launched a new product, SUTUREFIX, a suture anchor in February 2015. The product is expected to improve hip and shoulder repair by providing additional fixation points.

The industry is dominated by few players, while local implant manufacturers share the remaining market. DePuy Synthes, Stryker, Zimmer Biomet, and Medtronic and others are key players while Advanced Orthopedic Solutions, Emerge Medical, and Bioretec Ltd. are the emerging players in this vertical.

View summary of this report, Click Here 
Further Key Findings From the Study Suggest:

• Internal fixation dominated the market in 2015 due to the following associated advantages: shorter hospital stay, lesser scars and skin pressure, early functionality achieved in patients, and lesser risk of nonunion and malunion of bones. Industry players are adding new products with better functionality, which replicate the native anatomy, enhancing both, functionality and durability. In July 2016, the Acumed’s wrist fixation implants, Acu-Loc and Acu-Loc 2, reached a worldwide sales milestone of 0.5 million in 2 years. This indicates the high demand for internal fixation devices, which is expected to grow over the forecasted period.
• Amongst internal fixation methods, plates and screws are the most popular owing to the less blood loss involved and shorter operative time. This segment is expected to witness growth owing to the focus of companies on integrating different tools into one system. For instance, in July 2016, DePuy launched its locking hand system comprising 40 basic and specific plates for different cases of hand fractures. This aids the surgeons in adjusting the insertion specific to the patient’s bone anatomy to provide more stability.
• In 2015, North America dominated the market with a revenue share of more than 40%. The Affordable Care Act includes a separate grant for trauma care. Though this fund was discontinued in 2006, it was reauthorized in 2014 and set to an annual USD 12 million. The fund allocation aimed the improvement of trauma care centers in terms of access and quality, especially in the rural areas.

Click Here For Access Full Report : https://goo.gl/rCIesi

White Biotechnology Market Growth Is Expected To Reach USD 487.08 Billion By 2024

Rising awareness and emphasis for the adoption of greener and environment-friendly technologies in various end-use industries is expected to drive the market over the next eight years.

Biofuels accounted for over 35% of the market in terms of revenue on account of rising government regulations to include the product in combination with conventional energy sources including diesel and gasoline. Growing product use in the agricultural sector is likely to drive the demand over the next eight years.

Rising biodiesel demand as a raw material for the manufacturing of resins, and polymers will fuel industry growth over the forecast period. Volatility of crude oil prices is expected to encourage various manufacturers in the market to increase biofuel production over the next eight years which in turn will propel technology demand.

Increasing technology use in the manufacturing of various high-value products such as base chemicals, consumer chemicals and specialty chemicals is expected to positively impact industry growth. In addition, rising concerns regarding depletion of oil reserves and non-degradability of synthetic resources derived from oil are expected to boost the adoption of this technology in various regions particularly North America and Europe.

View summary of this report, Click Here 

Further key findings from the report suggest:

• Global white biotechnology market demand was 203.28 billion in 2015 and is expected to grow at a CAGR of 10.2% from 2016 to 2024.
• The biofuels segment is expected to grow at a CAGR of over 9% from 2016 to 2024. Advantages such as the ability to use directly in any unmodified diesel engine coupled with reduced particulate emissions are likely to fuel the growth of this industry over the next eight years.
• Food and feed additives application are expected to register a CAGR of around 10% from 2016 to 2024 accounting for over 20% of the total revenue in 2015. Rising use of this technology in improving the texture, edibility and extending the shelf life of perishable food products is expected to drive the growth over the forecast period.
• Biochemicals held the significant share, owing to its wide application scope in the chemical production process. Growing application scope of this technology on account of its use in efficient processing of chemicals is expected to drive the demand over the forecast period.
• Asia Pacific accounted for a significant share of over 20% in 2015. The ready availability of biobased raw materials coupled with cheaper manufacturing costs is expected to fuel the growth. The region is also projected to witness a growth of over 8% from 2016 to 2024.
• The industry is fragmented with a large number of major manufacturers present across the globe primarily in Europe and North America. Leading companies present in the global white biotechnology include DSM, Bayer, DSM, Evonik, Dow Chemicals, Henkel, BASF, DuPont, and LANXESS.
• BASF is involved in manufacturing chemicals, performance products, plastics, oil & gas and crop protection products. The company has six business segments including plastics, gas exploration & production, chemicals, performance products, agricultural products and functional solutions. In March 2015, BASF along with eight other companies launched a project called PRODIAS (Processing Diluted Aqueous Systems) which focuses on optimizing various production processes for renewable products

Click Here For Access Full Report : https://goo.gl/RWNq7S

Pharmacovigilance (PV) Software Market Is Expected To Reach A Value Of USD 207.3 Million By 2024

Increasing emphasis on regulatory compliances by government entities such as the U.S. FDA, European Medical Agency, etc. coupled with supportive initiatives are anticipated to drive the PV software market over the forecast period.

Increasing demand for fully integrated systems in an attempt to avert errors in database management is a crucial factor responsible for the adoption of these systems. Moreover, associated benefits of cloud-based platforms, such as remote access to information, reduction of operational costs, and ease of access are factors contributing toward the market growth in the near future.

View summary of this report, Click Here 

Further Key Findings from the Study Suggest:

• ADR reporting tools dominated the overall pharmacovigilance software market on the basis of functionality in 2015, due to the related benefits such as data entry and management with minimum errors. On the other hand, demand for fully integrated platforms is increasing to track individual case safety reports and avoid data redundancy through the elimination of errors. The aforementioned factors are anticipated to contribute toward lucrative growth of fully integrated systems in PV.
• On-demand software services, considered as cloud computing are expected to be the fastest growing service segment in the coming years due to its increasing adoption in the contract research organizations. Remote access to data, real-time data tracking, and a simpler complex physical ecosystem are the notable benefits associated with cloud-based systems.
• CROs segment is expected to exhibit profitable growth during the forecast period due to the increasing trend of outsourcing. PV service providers, in an attempt, to ensure sustainability, are providing customized end-to-end solutions to meet consumer needs. These firms are also incorporating integrated technologies, such as electronic data capture and hosting of PV warehousing to aggregate cross industry data, which enables risk evaluation. Furthermore, service providers are now operating via flexible and variable pricing structures to achieve operational excellence through constant product updates, which is expected to boost the usage rates over the next 7 years.
• North America held the largest market share as of 2015, majorly owing to the government aided initiatives favoring the adoption of PV software systems. For instance, the Open FDA initiative provides scientists and application developers the access to its massive database through open search-based programs, which is anticipated to boost the usage rates over the forecast period. Mini-Sentinel is a project started by the U.S. FDA to promote active surveillance systems, which provide statistically relevant data in less time. The aforementioned initiatives strengthen the growth of the regional market
• Many healthcare IT companies are shifting toward hosting of cloud-based platforms to gain an edge over the competition. Cloud-based technology helps in remote storage of large amounts of data to save free space on the devices and facilitates data retrieval as per client needs. The technology comprises 3 services including Platform as a Service (PaaS), Infrastructure as a Service (IaaS), and Software as a Service (SaaS)
• The key players serving pharmacovigilance software market are ArisGlobal, Ennov Solutions Inc.,Oracle Corporation, AB Cube, Sparta Systems, Inc., Max Application, EXTEDO GmbH, Relsys, Online Business Applications, Inc., and United BioSource Corporation

Reference Links: https://goo.gl/dBPhiF

Clinical Microbiology Market Growth Is Expected To Reach A Value Of USD 16.1 Billion By 2024

Key factors driving the market growth include constant introduction of advanced products coupled with increasing demand in pharmaceutical, and clinical applications for investigation and diagnosis of various infectious diseases.

The market is rapidly growing due to the increasing adoption of automated and advanced technologies for laboratory instruments and analyzers in developed countries. Growing geriatric population and thereby rising prevalence of infectious diseases is one of the major factors boosting the adoption of clinical microbiology in healthcare sector for disease diagnosis and monitoring. In addition, industry is gaining high momentum with launch of innovative products such as MALDI Biotyper, GeneXpert and Myla IT performance management solutions. Moreover, with the U.S. FDA approving the Xpert Carba-R, commercialization of clinical microbiology devices is expected to increase significantly over the next few years.

In North America, the government authorities and private companies have significantly contributed toward technology development, research funding, and commercialization of clinical microbiology associated devices.

View summary of this report, Click Here 

Further Key Findings from the Study Suggest:

• Rapid adoption of technology and automation of laboratory work flow, laboratory instrument segement is expected to be the fastest growing segment with CAGR of 8.6% over the forecast period.
• Reagents is the largest segment with market share of 34.7% in 2015. Repeat purchase of reagents contribute to its growth thus it is the largest growing segment in market.
• In 2015, North America dominated the global market with largest revenue share of 41.0%. The continuous research on infectious disease treatment, and subsequent grant from government healthcare agencies are contributing to the development of a strong ecosystem for the expansion of clinical microbiology in the region.
• Asia Pacific is expected to emerge as the fastest growing region during the forecast period. The growing geriatric population in India, China and Japan leading to increase in the prevalence of re-emerging infectious diseases such as tuberculosis, cholera and typhoid in this region are expected to promote the utilization of clinical application of microbiology in healthcare.
• The clinical microbiology Industry is presently dominated by a few key participants such as bioMerieux S.A., Cepheid Inc., Danaher Corporation and Bruker Corporation. Some of the prominent players operating in the market include but are not limited to Becton Dickinson & Company, Hologic Inc., Roche Diagnostics and Alere Inc. Introduction of automated systems and innovative designs, is expected to intensify the competition by changing the market dynamics over the forecast period.

Click Here For Access Full Report : https://goo.gl/k18t1S

Biological Safety Testing Market Growth Is Expected To Reach USD 5.54 Billion By 2024

The biological safety testing market is primarily driven by exponential growth in the production of biologics and medical devices that demand stringent safety requirements. The growing disease burden is anticipated to be the major cause for high production of biologics thus contributing toward market growth.

The overwhelming adoption rate of unhealthy lifestyles has resulted in the high prevalence of chronic diseases, such as cancer and diabetes, which is serving as a key contributing factor toward increasing drug development and their subsequent commercialization. This is presumed to raise the need to scrutinize and ensure the safety of targeted and specialized therapies, evaluate their outcomes, and circumvent probable shortcomings.

As a consequence of the high manufacturing intensity, pharmaceutical and biotechnology companies are increasingly incorporating biological safety testing tools to produce highly potent and contamination-free biologics to cater to the large population suffering from target diseases.

In addition, stringent regulations issued by healthcare organizations globally are presumed to be responsible for the high uptake of biological safety testing tools, thus resulting in a wider scope for the biological safety testing market

For instance, the European Medical Device Directives are believed to have a higher influence on the implementation of the defined imperative regulations to meet the growing safety requirements, thus translating into improved biological safety and contributing to overall growth of this vertical.

View summary of this report, Click Here

Further Key Findings From the Study Suggest:

• Reagents & kits held a substantial share of the product segment of over 42.0% in 2015 as it forms an indispensable part of the overall testing process and the high dependency of the testing results on the quality of reagents employed to perform the tests.

• In 2015, vaccine and therapeutics accounted for the largest market share in the application segment owing to the rising development of vaccines that are highly vulnerable to adventitious agents and necessitate stringent safety measures to prevent potential contamination due to unspecified agents

• The endotoxin tests held the largest share of 24.0% in the tests segment as of 2015. This large share is attributed to the high clinical urgency to reduce the threat of endotoxins during the development of bio-pharmaceuticals

• In 2015, North America dominated the regional biological safety testing vertical with a share of over 36.0%. The dominant share is a consequence of high investment in the biotechnology sector, its increasing adoption in cancer research, and for the development of new biologics, vaccines, and drugs.

• Asia Pacific is expected to witness growth at an exponential CAGR of over 13.0% during the forecast period. The exponential growth rate can be attributed to the increasing healthcare spending, the demand for better infrastructure quality in laboratory & clinical research, and the adoption of compact and low cost techniques in clinical research.

• The prominent players are involved in undertaking new product development and collaborative strategies to gain a higher share of the vertical. For instance, in June 2016, Charles River acquired Blue Stream Laboratories, Inc., an analytical contract research organization. This acquisition was carried out to enhance its existing capabilities in safety assessment and manufacturing of biologics.

Click Here For Access Full Report : https://goo.gl/BFDYWU

Electrodes For Medical Devices Market Growth Is Expected To Reach USD 2.0 Billion By 2025

The market is anticipated to witness lucrative growth during the forecast period, owing to increasing prevalence of chronic and other diseases such as heart diseases, Parkinson’s Disease (PD), Alzheimer’s disease, brain disorders, Trigeminal Neuralgia (TN or TGN), sinusitis, tinnitus, Raynaud's disease, fibromyalgia, circulatory disturbances, gout, and body ache, across the globe. 

Minimally Invasive Surgery (MIS) is one of the advancements in medical technology in which small incisions are made in the body for laparoscopy, endoscopy, arthroscopy, and other surgical procedures. This procedure is gaining popularity owing to faster recovery, lesser postsurgical infections, pain, & major bleeding, reduced scarring, and high accuracy benefits. In 2015, over 20.0 million Americans underwent MIS, which is expected to assist in the growth of this vertical during the forecast period.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• The diagnostic segment held a profitable revenue share in 2016 and is expected to grow at a significant rate over the forecast period.
• Rising prevalence of heart diseases, fetal distress syndrome, ocular diseases, and neurological disorders make extensive use of Electrocardiogram (ECG), Electroencephalogram (EEG), electrosurgical, and fetal scalp electrodes
• The therapeutic segment is anticipated to witness the fastest growth over the forecast period due to widened use of medical electrodes in aesthetic surgeries, RF ablation procedures, neurosurgical procedures, and acute & chronic pain treatments
• Defibrillator and electrosurgical electrodes are projected to hold substantial market share over the forecast period. This can be attributed to the advanced development of wearable defibrillator that constantly monitors the cardiac rhythms of the wearer and identifies & notifies the user about the occurrence of any abnormality and helps regain the normal heart functionality
• North America is expected to dominate the medical electrodes market during the forecast period, owing to the rising prevalence of CVDs, changing lifestyle of individuals, and presence of target population in the U.S. and Canada. In addition, the presence of advanced technologies with electrodes such as hydrogel and dry electrodes in the region are expected to spur the medical electrodes market growth.
• Some of the key players in medical electrodes market are 3M Healthcare; Boston Scientific Corporation; GE Healthcare; C.R Bard Inc.; CONMED Corporation; Medtronic; Natus Medical Incorporated; Thermo Fisher Scientific Inc.; Asahi Kasei Corporation; and Philips Healthcare

Click Here For Access Full Report : https://goo.gl/nVmyOV

Tourniquet systems market growth is expected to reach USD 594.8 million by 2025

Growing incidence of industrial & road accidents and major falls has been a major factor driving market growth. In addition, rapid increase in the number of hospitals and surgical care centers has led to increased application of tourniquets.

Tourniquets are majorly used when hemorrhages cannot be controlled with direct pressure or selective clamping of bleeding vessels. Certain advantages in modern surgical tourniquet systems such as safety, accuracy, and reliability have resulted in widespread adoption of these devices in orthopedic surgeries. Furthermore, technologically advanced tourniquet systems are now integrated with a wide range of pneumatic cuffs that help optimize the performance of the overall system. However, reusable cuffs might result in transmission of infection, which would consequently raise hospital costs and may hinder the growth of market during the forecast period.

View summary of this report, Click Here 

Further key findings from the report suggest:

• The market study suggests that tourniquet cuffs dominated the overall market in 2016 owing to their increasing applications in orthopedics, trauma, and emergency settings.
• Amongst the application segments, hospitals occupied the largest share as they are effective in arresting life‐threatening external hemorrhage caused due to limb injury
• In addition, the non-institutional application segment is expected to grow rapidly due to the potential application of tourniquets in military war settings.
• The Advanced Trauma Life Support (ATLS) recommends that “the judicious use of a pneumatic tourniquet may be helpful and lifesaving” in cases of major arterial hemorrhage caused by military wars
• North America dominated in 2016 owing to presence of an excellent healthcare infrastructure, rise in the number of road accidents, and increasing adoption of advanced tourniquet devices
• The Asia Pacific region is anticipated to witness significant growth during the forecast period. It will have one of the widest consumer base of tourniquets owing to huge population, increasing industrial & road accidents, and commendable financial support from various governments.
• Some of the major companies operating in this market are Delfi Medical, Zimmer Biomet, Hammarplast Medical AB, VBM Medizintechnik GmbH, Stryker, ulrich medical, and Rudolf Riester GmbH

Click Here For Access Full Report : https://goo.gl/JhKDGV

Perfusion Systems Market Growth Is Expected To Reach USD 183.8 Million By 2025

Rising demand for transplantation owing to increased incidence of vital organ failures is a major growth driver of the market. To curb this problem, Machine Perfusion (MP) is adopted by clinics. Hence, demand for the same is expected to grow over the coming years.

Statistics published by the National Kidney Foundation in 2014 states that 4,761 patients died due to unavailability of a kidney. This showcases the need for viable donated organs for transplantation, thereby boosting market growth.

The introduction of technologically advanced products for the purpose of enhanced efficiency and cost-effectiveness is expected to serve this market with lucrative opportunities. For instance, introduction of portable organ perfusion systems is presumed to gain popularity over the coming years owing to associated benefits with its usage such as ease of access, cost-efficiency, and portability.

Market participants are involved in extensive R&D for development of innovative perfusion techniques. For instance, TransMedics, Inc. carried out the world’s first warm blood perfusion liver transplantation with its innovative TransMedics Organ Care System Liver technology.

Moreover, many of market players in the U.S. and Europe are involved in the development of new products that are in clinical trials. For example, METRA developed by OrganOx Ltd. for automatic liver transportation and normothermic liver perfusion is under clinical study in the U.S. The expected product approvals in the coming years are anticipated to serve this industry with lucrative growth opportunities.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest: 

• Presence of government initiatives such as National Organ Transplant Programme in India and initiatives from nonprofit organizations such as Donate Life America in the U.S. are contributing toward increasing awareness level
• Introduction of warm blood perfusion technology is expected to offer this industry with future growth opportunities
• Hypothermic MP held the dominant share as of 2016 owing to increasing adoption for kidney preservation. These systems are capable of preserving an organ for a longer duration as compared to static cold storage. The associated benefits with the use of this technology is expected to fuel the demand
• The MP technology for kidney transplantation segment held a dominant share as of 2016 owing to benefits attached to its usage
• As of now, there are two MP systems that are approved by the U.S. FDA including LifePort Kidney Transporter by Organ Recovery Systems Inc. and WAVES RM3 by Waters Medical Systems
• The Asia Pacific regional industry for MP is expected to witness lucrative CAGR during the forecast period
• The industry participants are focusing toward the development of cost-effective solutions, thereby increasing R&D activities for the development of novel technologies.

Click Here For Access Full Report : https://goo.gl/mQ3R7f

Protein Expression Market Growth Is Expected To Reach USD 3.0 Billion By The Year 2025

The global protein expression market is expected to reach USD 3.0 billion by the year 2025 growing at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies,and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.

Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business.

View summary of this report, Click Here 

Further Key Findings From The Report Suggest:

• Prokaryotic expression systems segment was the largest revenue-generating amongst others owing to its large application in biologics and drug productions
• Mammalian cell expression systems is the fastest growing segment of the protein expression market owing to its growing demand for proteomics research and biologics manufacturing
• Reagents segment held the largest revenue share in the market, which is attributed to its repetitive purchase fortherapeutic, industrial, and research applications
• The services segment is projected to grow at highest rate due to increasing trend of outsourcing of protein expression services by research labs and drug manufacturers
• Therapeutic application segment was leading in 2016, due to high demand of therapeutic proteins for the treatment of cancer, infectious diseases, anemia, hemophilia, and multiple sclerosis
• The pharmaceutical and biotechnological companies segment dominated the sector in terms of revenue in 2016 due to rising focus on proteomics research and increasing production of biologics products
• North America was the leading regional market in 2016 and is expected to maintain its dominance during the forecast period, because of the presence of large number of biopharmaceutical and biotechnology companies in this region
• The Asia Pacific region is projected to grow at a highest CAGR during the forecast period owing to untapped opportunities in the developing countries including China and India

• Some of the major players include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, New England Biolabs, Promega Corporation, Qiagen, and Takara Bio, Inc.  

Click Here For Access Full Report : https://goo.gl/wju9Jf

Blood Culture Tests Market Growth Is Expected To Reach USD 6.6 Billion By The Year 2025

The increasing prevalence of bloodstream infections and infectious diseases is the most significant factor anticipated to propel the market growth during the forecast period. Increasing demand for advanced diagnostic techniques for the diagnosis of infectious diseases, such as sepsis, is the main factor that drives growth of the market. Thus, many manufacturing companies have begun focusing on development of advanced diagnostic instruments and consumables.

The introduction of various government initiatives pertaining to the prevention and control of infections is likely to propel the demand for blood culture tests. According to CDC, there was 46% decrease in central line-associated bloodstream infections between 2008 and 2013 in the U.S., owing to efforts taken by the U.S. government for the prevention of hospital-acquired infections.

View summary of this report, Click Here 

Further key findings from the report suggest:

• Conventional blood culture technique is the largest revenue-grossing segment owing to huge applications of this method in hospitals, independent clinical laboratories, and pathology laboratories
• In the product segment, consumables accounted for the largest revenue share in 2016, due their huge applications in diagnostics & research, with repetitive purchase of these consumables, such as blood culture media, assay, kits, and reagents, adding to the revenue
• Automated blood culture systems segment is the fastest growing segment of the blood culture tests market owing to the advantages of automation, such as low chances of error, faster result generation, etc.
• Molecular technology segment is projected to grow at the highest CAGR, because of increasing demand for advanced products by hospitals and laboratories for diagnosis of infectious diseases
• Bacterial infections accounted for the largest revenue share in 2016, due to the fact that they are the most common cause for infection in the blood
• Reference laboratories is projected to grow at the highest rate during the study period, because there is an increase in outsourcing of blood tests by hospitals to reference laboratories
• North America is the leading regional sector that accounted for the largest revenue share of the blood culture tests market in 2016, because of the presence of well-developed healthcare infrastructure in this region
• The Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period owing to increased focus of government on the prevention of infectious diseases
• Some of the major players are Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; Danaher Corporation; Luminex Corporation; Roche Diagnostics; Bruker Corporation; Abbott Laboratories; and Alere

Click Here For Access Full Report : https://goo.gl/Cpz4aZ